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Background: The safety of once-daily (qd) dosing of valsartan in heart failure (HF) patients 
is not known.
Hypothesis: This 10-week, double-blind trial examined the relative safety and efficacy of 
valsartan administered qd versus twice-daily (bid).
Methods: HF patients (NYHA class II–III) receiving diuretics (87%), angiotensin-converting 
enzyme inhibitors (98%), beta-blockers (92%), aldosterone antagonists (25%), or digoxin 
(32%) were randomized to valsartan 40 mg bid (n = 60) or 80 mg qd (n = 55) and titrated to 
a maximum dose of 320 mg/day; doubling the dose every 2 weeks. Clinical and biochemical 
parameters were measured at Weeks 2, 4, 6, and 10.
Results: The average dose of valsartan at the end of study was 245 mg in the bid group vs 
256 mg in the qd group (P = NS). Similar proportions of patients tolerated qd vs bid dosing 
(bid 67% vs qd 68%). Outcome measures including reduction in blood pressure, incidence of 
hypotension, renal impairment, orthostatic dizziness or fatigue, changes in serum K+, creatinine, 
cystatin-C, and estimated glomerular filtration rate were similar between the 2 groups at all 
time-points. Brain natriuretic peptide levels decreased and plasma renin activity increased from 
baseline by the same amount in both groups at all time-points.
Conclusion: Valsartan administered qd has a similar safety and tolerability profile with com-
parable 24-hour RAAS blockade, as assessed by increases in PRA, as bid dosing in patients 
with moderate to severe (NYHA class II–III) heart failure.
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Introduction
The renin-angiotensin-aldosterone system (RAAS) is activated in patients with chronic 
heart failure (CHF) and its inhibition with beta-blockers and/or angiotensin-converting 
enzyme inhibitors (ACE-I) is associated with reductions in cardiovascular mortality 
and morbidity.1–6 Current CHF treatment guidelines recommend the use of angiotensin 
receptor blockers (ARBs) as reasonable alternatives to ACE-I or in patients on ACE-I 
who remain symptomatic.7–9 Two large randomized trials demonstrated a significant 
reduction in morbidity when an ARB was added in patients with New York Heart Asso-
ciation (NYHA) class II–IV CHF receiving prescribed therapies of ACE-I, diuretic, 
and beta-blocker.10–11 In the Valsartan Heart Failure Trial (Val-HeFT), valsartan was 
administered twice-daily (160 mg bid), despite being effective once daily (qd) in hyper-
tension, to ensure sustained inhibition of the angiotensin II type 1 (AT1) receptor.12,13 
Currently, valsartan is approved for use with bid dosing in the treatment of heart failure 
in patients who cannot use an ACE-I or as add-on therapy for patients already taking an Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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ACE-I. We evaluated the tolerability, safety, and effectiveness 
of RAAS blockade after valsartan qd vs bid dosing in patients 
with stable heart failure (NYHA class II–III).
Methods
The Diovan Evaluation of Safety TwIce vs oNce dailY study 
in Heart Failure (DESTINY-HF) trial was a multicenter 
(34 sites), randomized, double-blind, active-controlled, 
parallel-group trial. Written informed consent was obtained 
from all patients.
eligibility
Patients were recruited based on the inclusion criteria set 
originally for Val-HeFT.12 Adult men and women with a 
history and clinical documentation of stable heart failure 
(NYHA class II–III) and left ventricular systolic dysfunc-
tion (ejection fraction ,40%, measured within 3 months 
before screening) were eligible. Patients had to have been 
receiving stable doses of ACE-I and beta-blockers for at 
least 3 months and all other standard-care medication for 
heart failure (eg, diuretics, digoxin) for at least 2 weeks 
prior to screening. Investigators were instructed to keep each 
patient’s heart failure medication constant during the trial. 
Dose adjustments were not encouraged except for adverse 
events (eg, for reasons of hypotension, renal insufficiency, 
worsening CHF symptoms) during the study.
Exclusion criteria included standing blood pressure (BP) 
,95 mmHg; serum creatinine .2.5 mg/dL; serum potassium 
.4.8 mmol/L; and treatment with ARBs, including valsartan, 
within the 3 months prior to screening. In addition, pregnant, 
nursing women, and women of child-bearing potential who 
were not practicing effective contraceptive methods were 
excluded.
study design
Qualifying patients entered a 10-week, double-blind treatment 
and were randomly assigned to 1 of the following parallel 
arms: (a) valsartan 80 mg qd for 2 weeks, titrated to a maxi-
mum of 320 mg qd, by doubling the dose every 2 weeks or 
(b) valsartan 40 mg bid for 2 weeks, titrated to a maximum 
of 320 mg administered as 160 mg bid, by doubling the dose 
every 2 weeks.
On the morning of any scheduled study clinic visit, 
patients were instructed not to take their study medication 
until after all study evaluations had been completed at the 
clinic. The reason (medical condition) why a patient could 
not be up-titrated at Weeks 2 and 4 was documented.
Outcome variables
The primary outcome variable was the percentage of patients 
who could tolerate the qd vs bid dosing regimen at Week 10. 
Table  1  Baseline  characteristics  of  the  patients  according  to 
treatment group
Baseline characteristic Valsartan bida 
n = 60
Valsartan qda 
n = 55
Age, years ± sD 67.3 ± 11 63.4 ± 11
Male, n (%) 50 (83.3) 41 (74.5)
Race, n (%) 
  White 49 (81.7) 43 (78.2)
  Black 5 (8.3) 10 (18.2)
Physiological measurements, mean ± SD
Body mass index (kg/m2) 29.7 ± 6 31.2 ± 7 
sitting sBP (mmHg) 120 ± 18 125 ± 17
standing sBP (mmHg) 120 ± 18 124 ± 17
sitting DBP (mmHg) 70 ± 10 74 ± 11
standing DBP (mmHg) 71 ± 11 74 ± 11
sitting heart rate (bpm) 68.4 ± 11 70.4 ± 10
standing heart rate (bpm) 71 ± 11 73.9 ± 11
NYHA class, n (%)
class ii 44 (73.3) 34 (61.8)
class iii 16 (26.7) 21 (38.2)
Medical history, n (%)b
coronary heart disease 41 (68) 27 (49)
Myocardial infarction 29 (48) 23 (42)
ischemic cardiomyopathy 9 (15) 12 (22)
Angina pectoris 18 (30) 19 (34)
Atrial fibrillation 12 (20) 14 (25)
Hypertension 36 (60) 45 (82)
Diabetes 27 (45) 22 (40)
chronic kidney disease 8 (13) 7 (13)
cOPD 14 (23) 5 (9)
Anemia 4 (7) 9 (16)
Laboratory measurements, mean ± SD
serum potassium (meq/L) 4.47 ± 0.4 4.33 ± 0.4
BUn  22.8 ± 10 22.4 ± 12
serum creatinine (mg/dL) 1.25 ± 0.5 1.20 ± 0.4
egFR based on serum creatinine 
(mL/min/1.73 m2)
67.1 ± 21 70.6 ± 25
cystatin-c (mg/L) 1.5 ± 0.6 1.4 ± 0.4
egFR based on serum cystatin-c 
(mL/min/1.73 m2)
66.1 ± 23 70.2 ± 25
Hemoglobin (g/dL) 14.3 ± 2 14.5 ± 2
Background therapy, n (%)
Ace-inhibitor 59 (98) 54 (98)
Beta blocker 56 (93) 50 (91)
Diuretic 52 (87) 48 (87)
Digitalis glycosides 18 (30) 19 (34)
Aldosterone antagonist 13 (22) 16 (29)
abid dosing = 40 mg, 80 mg, or 160 mg and qd dosing = 80 mg, 160 mg, or 320 mg; 
binvestigator reported.
Abbreviations: Ace,  angiotensin  converting  enzyme;  BUn,  blood  urea  nitrogen; 
cOPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; egFR, 
estimated glomerular filtration rate; NYHA, New York Heart Association; SBP, systolic 
blood pressure; sD, standard deviation. Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Inability to tolerate the dosing regimen was defined by any 
of the following: serum potassium $6.0 mEq/L, elevations 
in serum creatinine $2.5 mg/dL and increased by .50% 
from baseline, reduction in standing systolic blood pressure 
(SBP) to ,90 mmHg, symptoms related to hypotension 
(eg, syncope, faintness, or orthostatic dizziness), or worsen-
ing of NYHA functional class.
The secondary end points were percentage of patients 
reaching the target total daily dose of 320 mg and NYHA 
classification status at Week 10. Change from baseline to 
Week 10 in SBP, diastolic blood pressure (DBP), serum 
potassium, estimated glomerular filtration rate (eGFR) based 
on serum creatinine and serum cystatin-C,14 brain natriuretic 
peptide (BNP), and plasma renin activity (PRA) were other 
secondary variables measured.
statistical analysis
The tolerability rate at Week 10 was calculated using both 
last-observation-carried-forward (LOCF) and observed-
cases methods for the primary end point and categorical 
secondary end point (percentage of patients reaching target 
daily dose of 320 mg and NYHA classification status at 
Week 10). Cochran-Mantel-Haenszel chi-square test adjust-
ing for pooled center and a 95% confidence interval (CI) 
was used to calculate the difference between the 2 treat-
ment groups. For the continuous secondary variables, an 
analysis of covariance model with baseline measurement, 
pooled center, and treatment as covariates/factors was used. 
Mean differences, least squares mean differences, 95% 
CIs, and treatment P-value (significance level of 0.05) for 
the comparisons of the 2 treatment groups were reported. 
Because of the non-normal distribution of BNP and PRA 
data, non-parametric statistical analyses (Wilcoxon) were 
also performed.
Results
Of the 195 patients screened, 115 were randomized (55 
qd group, 60 bid group). Twenty-nine patients (17 bid 
group, 12 qd group) withdrew prior to completion of 
the study, 25 for adverse events and 4 for withdrawal 
of consent.
There were no clinically relevant or statistically sig-
nificant differences in the baseline characteristics of the 
2 groups (Table 1). Overall, mean age was 65 years; 79% 
were male, 80% were white, and 57% were 65 years of age 
or older. All patients were either in NYHA class II (68%) 
or class III (32%). At randomization, 98% of patients 
were being treated with an ACE-I; 92% were receiving 
beta-blockers, 87% diuretics, 32% digoxin, and 25% 
spironolactone.
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Figure 1 Percentage of patients tolerating valsartan once-daily (qd) or twice-daily (bid) dosing regimen using observed cases. Using data from observed cases, the percentage 
of patients able to tolerate the dosing regimen at the end of the study was 78% for bid dosing and 72% for qd dosing (P = 0.56). inability to tolerate the dosing regimen 
was defined as any of the following: serum potassium $6.0 meq/L, elevations in serum creatinine $2.5 mg/dL and increased by .50% from baseline, reduction in standing 
sBP (,90 mmHg), symptoms related to hypotension (eg, syncope, faintness, or orthostatic dizziness), worsening of NYHA functional class (eg, fatigue or breathlessness) in 
patients with stable CHF (NYHA class II–III).Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Dose of valsartan
The target dose of 320 mg daily was achieved by 67% of 
patients in the bid group vs 71% in the qd group by study 
end. The average dose of valsartan at study end was 245 mg 
and 256 mg in the bid and qd groups, respectively.
safety
Valsartan was well tolerated with no differences observed 
between treatment groups. At Week 10, 35/45 (78%) patients 
in the bid group and 33/46 (72%) in the qd group were able to 
tolerate valsartan. The difference between treatment groups 
(6.0%) was not statistically significant (Figure 1). At study 
end (LOCF criteria), 68% of patients (36/53) in the qd group 
tolerated the dosing regimen compared to 67% (38/57) in the 
bid group. There were no differences between the 2 dosing regi-
mens for any of the individual tolerability criteria (Table 2).
The investigator-reported adverse events and serious 
adverse events are also listed in Table 2. There were no 
treatment-related differences in the incidence of adverse events. 
Examining adverse events specifically related to low BP (dizzi-
ness, hypotension, and syncope), they were found to be similar 
between the qd (n = 29, 53%) and bid groups (n = 26, 43%). 
Serious adverse events were reported in 7 patients in the bid 
group and 3 in the qd group. There were 25 (22%) patients who 
withdrew from the study due to adverse events (eg, dizziness, 
fatigue, worsened CHF, hypotension, diarrhea, and syncope): 
14 (23%) in the bid group and 11 (20%) in the qd group.
Laboratory measures
No significant difference between the qd and bid groups 
was seen in change from baseline to study end (Week 10) in 
secondary outcome variables (Table 3). There was a small 
increase from baseline in serum potassium (0.08 mEq/L 
in the bid group vs 0.01 mEq/L in the qd group), with no 
significant difference between either treatment group. There 
was a significant reduction in eGFR (estimated using serum 
creatinine levels or cystatin-C); however, there was no dif-
ference between the 2 dosing regimens.
Efficacy: change in blood pressure
There was a small reduction in SBP and DBP in the qd group 
compared to the bid group, but no significant difference 
between the 2 dosing regimens (Table 3).
Efficacy: BNP and PRA
BNP levels decreased similarly after 2 weeks of treatment in 
both groups, but thereafter levels did not change   significantly 
Table 2 Tolerability of valsartan once-daily versus twice-daily 
dosing during the study
Tolerability criteria, n (%)a Valsartan bidb 
n = 60
Valsartan qdb 
n = 55
serum potassium .6.0 meq/L 0 (0) 0 (0)
serum creatinine .2.5 mg/dL  
and .50% increase
1 (1.7) 0 (0)
standing sBP ,90 mmHg 0 (0) 4d (7.3)
symptoms related to hypotension 16 (26.7) 14 (25.4)
Worsening NYHA functional class 4 (6.7) 2 (3.6)
Total patients with Aes, n (%)c 50 (83.3) 47 (85.5)
  congestive heart failure 6 (10.0) 3 (5.5)
  Hypotension  4 (6.7) 2 (3.6)
  Diarrhea 3 (5.0) 5 (9.1)
  Fatigue 18 (30.0) 12 (21.8)
  Dizziness 12 (20.0) 11 (20.0)
  Dizziness, postural 7 (11.7) 13 (23.6)
  Headache 2 (3.3) 5 (9.1)
  Dyspnea 7 (11.7) 5 (9.1)
  Dyspnea, exertional  5 (8.3) 5 (9.1)
serious Aes, n (%)c 7 (11.7) 3 (5.5)
  Angina pectoris 1 (1.7) 0 (0)
  Atrial fibrillation 1 (1.7) 0 (0)
  congestive heart failure 3 (5) 1 (1.8)
  Metastatic hepatic cancer 1 (1.7) 0 (0)
  Acute renal failure 1 (1.7) 0 (0)
  Hypotension 0 (0) 1 (1.8)
  Hyperglycemia 0 (0) 1 (1.8)
  serum potassium increased 1 (1.7) 0 (0)
aUsed as one of the criteria to determine inability to tolerate the dosing regimen; bbid 
dosing = 40 mg, 80 mg, or 160 mg and qd dosing = 80 mg, 160 mg, or 320 mg; cinvestigator 
reported. dP = 0.03.
Abbreviations: AE, adverse event; bid, twice-daily dosing; NYHA, New York Heart 
Association; qd, once-daily dosing; sBP, systolic blood pressure. 
Table 3 Efficacy parameters: change from baseline at week 10/end of study
Parameter, mean Valsartan bid 
n = 60
Valsartan qd 
n = 55
P value: 
bid vs qd
sitting sBP (mmHg ± sD) -1.7 ± 16 -2.9 ± 15 0.98
sitting DBP (mmHg ± sD) -0.04 ± 8 -1.5 ± 10 0.82
serum potassium (meq/L ± sD) 0.08 ± 0.4 0.02 ± 0.4 0.09
serum creatinine (mg/dL ± sD) 0.14 ± 0.4 0.07 ± 0.2 0.55
serum cystatin-c (mg/L ± sD) 0.09 ± 0.3 0.06 ± 0.2 0.51
egFR, serum creatinine (mL/min/1.73 m2 ± sD) -5.0 ± 13 -5.6 ± 14 0.94
egFR serum cystatin-c, (mL/min/1.73 m2 ± sD) -4.4 ± 14 -3.3 ± 13 0.20
BUn (mg/dL ± sD) 4.4 ± 8.4 2.4 ± 7.5 0.89
Abbreviations: bid, twice-daily dosing; BUN, blood urea nitrogen; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; qd, once-daily dosing;   
sBP, systolic blood pressure; sD, standard deviation.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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egy with bid dosing in heart failure; however, 2 trials using 
valsartan 160 mg qd have reported comparable efficacy and 
safety to either enalapril 20 mg/d18 or lisinopril 20 mg/d19 
in this population.
effect of valsartan on PRA and BnP levels
We have previously shown that the use of valsartan 160 mg 
bid in CHF patients receiving background ACE-I therapy is 
associated with an increase in PRA.13 Similar findings have 
been reported in patients with chronic kidney disease.20 This 
suggests inadequate RAAS blockade by ACE-I alone that 
could be related to the dose of background ACE-I use.21 
Although most patients in our study (98%) were receiving 
background ACE-I therapy, only 27% were receiving the 
target dose for their respective ACE-I. Furthermore, 43% 
(49/115) of patients were on an ACE-I dose below that rec-
ommended for treatment of CHF.7,22 Thus, the rise in PRA 
observed in both bid and qd valsartan dosing groups confirms 
additional blockade of the RAAS.
It is important to note that the PRA response in patients 
receiving an ACE-I or ARB can serve as an index of RAAS 
suppression. The similar increase in PRA between both 
dosing strategies in this study suggests similar effects of qd 
versus bid dosing of valsartan on the blockade of the RAAS 
over the 24-hour period. Previous studies have demonstrated 
that using valsartan 160–320 mg qd provides effective AT1 
receptor blockade throughout the 24-hour period.23,24 Taken 
together, these findings and our PRA results suggest that 
valsartan 160–320 mg, given either once or twice a day, 
can achieve effective blockade of the RAAS throughout the 
24-hour period. Moreover, a similar PRA response to qd 
and bid dosing of valsartan in this study suggests that both 
regimens had a similar level of treatment compliance.
in either group from baseline (Table 4). PRA increased 
  significantly in both groups, and there was no significant 
difference between the 2 treatment groups at any time-point 
(Table 4).
Efficacy: change in NYHA class  
from baseline
There were no significant changes in the NYHA class between 
the qd and bid groups. A total of 87% patients in both the qd 
and bid groups had no change in their NYHA class. No patient 
worsened to class IV in either treatment group. There were no 
statistically significant differences between treatment groups in 
the change in NYHA class from baseline at any study visit.
Discussion
We compared the use of valsartan in a bid dosing regimen, as 
used in Val-HeFT, to qd dosing in patients with stable heart 
failure (NYHA class II–III). Valsartan was well tolerated 
with a similar proportion of patients in both dosing groups 
achieving the target dose of 320 mg/d by study end. The mean 
daily dose of valsartan achieved in this study (245 mg in bid 
vs 256 mg in qd group) was similar to the 254-mg/d dose 
reported in Val-HeFT.10 In addition, primary and secondary 
outcome variables were not different between the 2 dosing 
groups and were similar to those observed in Val-HeFT.10
For the treatment of hypertension, all ARBs, including 
valsartan, are recommended in qd dosing. The qd indication 
for valsartan was based primarily on the 24-hour BP-lowering 
efficacy of 80–320 mg.15,16 When qd dosing of valsartan at 
160 mg was compared with bid dosing of valsartan at 80 mg, 
a similar reduction in SBP and DBP was observed.17 Despite 
evidence supporting qd use of valsartan in hypertension, no 
clinical studies have compared the tolerability of this strat-
Table 4 change from baseline in brain natriuretic peptide and plasma renin activity, by week
Week BNP, mean pg/mL ± SD BNP, median pg/mL 
(95% CI)
PRA, mean ng/mL ± SD PRA, median ng/mL/h 
(95% CI)
Valsartan 
bid
Valsartan 
qd
Valsartan 
bid
Valsartan 
qd
Valsartan 
bid
Valsartan 
qd
Valsartan 
bid
Valsartan 
qd
Baseline 295 ± 417 241 ± 400 119.5 123.0 5.1 ± 6 5.1 ± 6 3.1 2.5
Change from baseline
Week 2 -58 ± 183a -16 ± 144 -19.0a 
(-108, -8)
-11.5a 
(-57, 25)
3.0 ± 6a 1.9 ± 6a 1.2a 
(1.1, 4.8)
1.0a 
(0.2, 3.6)
Week 4 -16 ± 262 -29 ± 138 -18.0 
(-91, 60)
-3.0 
(-70, 11)
3.3 ± 9a 2.1 ± 6a 0.6a 
(0.8, 5.8)
0.6a 
(0.2, 4.0)
Week 6 -4 ± 329 -32 ± 244 -9.0 
(-101, 94)
-8.0 
(-104, 41)
2.2 ± 6a 1.1 ± 5 1.4a 
(0.4, 4.0)
0.4 
(-0.3, 2.6)
Week 10 30 ± 564 -39 ± 213 -17.0 
(-139, 157)
-19.0 
(-102, 24)
2.1 ± 7 3.0 ± 7a 0.3 
(-0.3, 4.4)
1.0a 
(0.6, 5.4)
aP , 0.05 vs baseline.
Abbreviations: bid, twice-daily dosing; BNP, brain natriuretic peptide; CI, confidence interval; PRA, plasma renin activity; qd, once-daily dosing; SD, standard deviation.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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In Val-HeFT, the addition of valsartan to heart failure 
patients resulted in significant reductions of BNP, close to 
what was reported herein. The Val-HeFT study reported 
reductions from 16–34 pg/mL in BNP during the course of 
study with average reductions of 21 pg/mL.25 The similar 
BNP response reported for both dosing groups in our study 
suggests that valsartan has a similar effect on BNP, regardless 
of the dosing interval.
Conclusions
This study demonstrates that qd dosing with valsartan has a 
similar safety and tolerability profile to that of bid dosing in 
patients with NYHA class II–III heart failure. Additionally, 
treatment with qd-dosed valsartan results in similar 24-hour 
RAAS blockade to that seen following bid dosing, as assessed 
by increases in PRA.
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